Day: March 7, 2025

Includes one Extended Timeline Pool Offering Targeting Smaller Investors MCLEAN, Va., March 07, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) announced today it will offer approximately $290 million in non-performing loans (NPL) for sale via auction. The NPLs being offered consist of seasoned, deeply delinquent residential first lien whole loans held in Freddie Mac’s mortgage-related investments portfolio. The NPLs are currently serviced by Select Portfolio Servicing Inc., Newrez LLC, d/b/a Shellpoint Mortgage Servicing or Nationstar Mortgage LLC, d/b/a Rushmore Servicing. The NPLs are being marketed via four pools: three Standard Pool Offerings (SPO®) and one Extended Timeline Pool Offering (EXPO®), which targets participation by smaller investors, including non-profits and Minority, Women, Disabled, LGBTQ+, Veteran or Service-Disabled...

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fireside chat on Wednesday, March 12, 2025, at 9:30-9:55 am EDT (13:30-13:55 GMT). An audio webcast of the fireside chat will also be available to investors and the general public and can be accessed in the Events Section of Alvotech’s Investor Portal. After the event, a recording will also be available for 90 days. About AlvotechAlvotech is...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fireside chat on Wednesday, March 12, 2025, at 9:30-9:55 am EDT (13:30-13:55 GMT). An audio webcast of the fireside chat will also be available to investors and the general public and can be accessed in the Events Section of Alvotech’s Investor Portal. After the event, a recording will also be available for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely...

Owner of TCL Chinese Theatre and Dolby Theatre to Provide Strategic Guidance, Expanding Access to Premier Industry Venues and Relationships LOS ANGELES, March 07, 2025 (GLOBE NEWSWIRE) — Stargaze Entertainment Group Inc. (“Stargaze” or the “Company”) (OTC: STGZ), a content creation and social platform designed to redefine talent discovery, has appointed renowned film producer and entertainment mogul Elie Samaha to its Advisory Board. This addition is set to strengthen Stargaze’s industry influence and expand opportunities for emerging talent. As a key public figure in Hollywood, Samaha’s ownership of two of the most iconic venues in entertainment provides Stargaze with unprecedented access to industry-defining spaces, including the TCL Chinese Theatre, a historic movie palace on the Hollywood Walk of Fame, and the Dolby Theatre,...

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development, and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, announced the release of its 2024 Sustainability Report on March 6, 2025. “As a Company, we recognize in order to ‘Leave It Better,’ we need to focus on creative and innovative approaches to sustainability,” said Pat D’Eramo, CEO. “Our team continues to drive advancements in product development, manufacturing efficiencies and technology implementation, ensuring we adapt to an ever-evolving industry while creating a more sustainable future.” “Our commitment to ‘Making People’s Lives Better’ is at the core of everything we do,” said Rob Wildeboer, Executive Chairman. “This...

Hamilton, March 07, 2025 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for a patent (application #17/466,142) relating to the composition of Bentrio®, a nasal spray developed and commercialized by its affiliate Altamira Medica AG (“Medica”) for preventing or treating allergic rhinitis. The claims are directed to the key ingredients and composition of Bentrio’s proprietary formulation. The patent, upon issuance, will have an initial priority date of September 8, 2020, and is expected to provide key intellectual property protection for Bentrio in the USA, the world’s largest market for “over the counter (OTC)” products for allergic rhinitis relief and treatment. “We are very pleased to have achieved this...

AS Inbank has proposed the following amendments to the Inbank Articles of Association for approval at the Annual General Meeting of Shareholders on 31 March 2025: 6.3 The Supervisory Board has a right, within 3 (three) years as of the entry into force of the version of the articles of association, to increase the share capital by monetary contributions by EUR 76,000, i.e. to increase the share capital to the amount of EUR 1,227,966.30. 7.9 The Bank may be represented in transactions and legal operations by two members of the Management Board jointly. A person acting in the name of the Bank may not represent the Bank in concluding transactions or holding legal disputes with a third person with regard to whom the person acting in the name of the Bank or a person with an economic interest equivalent to that of such person has personal economic...

Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA6000, the first clinical stage asset which is a pre|CISION®-enabled form of doxorubicin, has completed the Phase 1a dose escalation with encouraging PFS data in patients with salivary gland cancers. The Company has initiated enrollment in the Phase 1b expansion cohorts with multiple patients treated. Promising early efficacy and safety signals are observed in the Phase 1a trial. As of the most recent data...